Analystreport

Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $89.00 price target on the stock.

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com